ALT5 Sigma (NASDAQ:ALTS) Director David Danziger Buys 10,000 Shares

Key Points

• ALT5 Sigma Director David Danziger purchased 10,000 shares at $7.30 each, increasing his total ownership to 20,000 shares.
• Several analysts have a bearish outlook on ALT5 Sigma, with Weiss Ratings issuing a "sell (d-)" rating and Wall Street Zen downgrading it to a "strong sell".
• Institutional investors now hold 6.27% of ALT5 Sigma's shares, with notable acquisitions from firms like Jane Street Group and Geode Capital Management.

ALT5 Sigma Corporation (NASDAQ:ALTS - Get Free Report) Director David Danziger bought 10,000 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were acquired at an average cost of $7.30 per share, with a total value of $73,000.00. Following the completion of the purchase, the director owned 20,000 shares in the company, valued at $146,000. This represents a 100.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

ALT5 Sigma Price Performance

NASDAQ ALTS traded up $0.02 during trading hours on Thursday, reaching $2.81. 4,803,716 shares of the company's stock were exchanged, compared to its average volume of 3,230,219. The company's 50-day moving average is $5.08 and its two-hundred day moving average is $6.28. ALT5 Sigma Corporation has a one year low of $1.65 and a one year high of $10.95. The company has a debt-to-equity ratio of 1.45, a current ratio of 0.88 and a quick ratio of 0.88.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ALTS. Weiss Ratings reiterated a "sell (d-)" rating on shares of ALT5 Sigma in a report on Wednesday. Wall Street Zen cut shares of ALT5 Sigma from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 16th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of "Sell".

Institutional Investors Weigh In On ALT5 Sigma

A number of hedge funds and other institutional investors have recently modified their holdings of ALTS. Jane Street Group LLC acquired a new stake in shares of ALT5 Sigma during the second quarter worth $380,000. Geode Capital Management LLC raised its stake in ALT5 Sigma by 27.6% in the second quarter. Geode Capital Management LLC now owns 194,813 shares of the company's stock valued at $1,412,000 after purchasing an additional 42,157 shares in the last quarter. Evernest Financial Advisors LLC acquired a new position in ALT5 Sigma in the second quarter valued at about $87,000. Finally, Bridgeway Capital Management LLC raised its stake in ALT5 Sigma by 9.4% in the second quarter. Bridgeway Capital Management LLC now owns 19,339 shares of the company's stock valued at $140,000 after purchasing an additional 1,661 shares in the last quarter. Institutional investors and hedge funds own 6.27% of the company's stock.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.